Is Doxylamine-Pyridoxine Effective for Pregnancy-Related Nausea and Vomiting?

January 18, 2018

The researchers found that the improvement in symptom scores was greater with doxylamine-pyridoxine versus placebo (0.73 points; 95% confidence interval, 0.21 to 1.25) when the last observation carried forward imputation was used for missing data.

Varubi Labeling Updated to Warn of Serious Hypersensitivity Reactions

By January 16, 2018

Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported.

Effective Treatments for Nausea, Vomiting of Pregnancy

December 28, 2017

Early treatment can prevent complications; safe, effective treatment available for more severe cases

New Formulation of Varubi Launched for Delayed CINV

By November 28, 2017

Varubi is a highly selective and potent antagonist of human substance P/neurokinin 1 (NK-1) receptors.

Cinvanti Approved for Chemotherapy-Induced Nausea and Vomiting

By November 10, 2017

The approval of Cinvanti was supported by Phase 2 bioequivalence data of Cinvanti and Emend IV (fosaprepitant dimeglumine; Merck), where patients treated with Cinvanti experienced fewer adverse events vs. patients treated with Emend IV, including substantially fewer infusion-site reactions.

Recall: Syringes Labeled for Sedation Med Instead Contain Antiemetic

By November 06, 2017

Dose-dependent serious cardiac arrhythmias may be observed with higher dosages of ondansetron in those patients with certain pre-existing cardiac conditions.

Varubi IV Approved for Delayed Chemotherapy-Induced Nausea/Vomiting

By October 26, 2017

Varubi, a highly selective and competitive antagonist of human substance P/neurokinin (NK-1) receptor, is already available as 90mg strength tablets.

Old Anti-Nausea Agent May Be Effective for Sleep Apnea

By June 07, 2017

"Expanded and pivotal clinical trials must still be conducted to fully establish the best approach to cannabinoid therapy in obstructive sleep apnea," said lead author Professor David Carley.

FDA Approves Final Label for Syndros with CII Designation

By May 24, 2017

Syndros is the first FDA-approved dronabinol solution for oral administration, containing the pharmaceutical version of tetrahydrocannabinol (THC).

Motion Sickness Drug May Worsen Vestibular Perception

By April 24, 2017

The researchers concluded that a person's ability to perceive motion was significantly lowered while taking oral promethazine.

Are Antiemetic Prophylactics Being Overprescribed for Chemotherapy?

By March 24, 2017

Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.

DEA Designates Syndros as Schedule II Drug

By March 23, 2017

Syndros is anticipated to launch in the second half of 2017. It will be available as a 5mg/mL strength oral solution.

Rescue Tx for Post-Op Nausea/Vomiting Effective in Pivotal Trial

By February 13, 2017

Acacia has announced positive results from its final pivotal Phase 3 study investigating BAREMSIS (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea and vomiting (PONV), despite having received prior antiemetic prophylaxis.

Drug Patch Recalled Due to Incorrect Dosing Instructions

By February 06, 2017

Sandoz announced a voluntary recall of three lots of Transderm Scop (scopolamine) patches due to a discrepancy in the product labeling for the pouches and outer carton.

Cinvanti NDA Submitted for CINV Prevention

By January 12, 2017

Heron Therapeutics announced the submission of the New Drug Application (NDA) for Cinvanti (HTX-019) to the Food and Drug Administration (FDA) for the prevention of chemotherapy-induced nausea and vomiting (CINV).

FDA Announces Antiemetic Drug Discontinuation

By November 17, 2016

The Food and Drug Administration (FDA) has posted a discontinuation notice for Zofran Oral Solution (ondansetron; Novartis).

FDA Approves Bonjesta for Pregnancy-Related Nausea and Vomiting

By November 11, 2016

The Food and Drug Administration (FDA) has approved Bonjesta (doxylamine succinate and pyridoxine HCl extended-release tablets; Duchesnay), a fixed-dose combination drug product for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

Motion Sickness Patch Currently in Shortage

By September 16, 2016

The Food and Drug Administration (FDA) is reporting a current backorder status for Transderm Scop (scopolamine; Sandoz) 1.5mg patches.

Anti-Nausea Drug Evaluated in Acute Food Protein-Induced Enterocolitis Syndrome

By August 22, 2016

A retrospective study found that the nausea and vomiting preventative treatment, ondansetron, was more effective than traditional therapy in inducing remission of vomiting in patients with acute food protein induced enterocolitis syndrome (FPIES).

Baremsis Demonstrates Efficacy for Post-Op Nausea and Vomiting

By August 12, 2016

Acacia Pharma announced positive data from the Phase 3 study of Baremsis (amisulpride) for the potential treatment of post-operative nausea & vomiting (PONV).

Sustol Approved for Chemotherapy-Induced Nausea and Vomiting

By August 10, 2016

Heron announced that the Food and Drug Administration (FDA) has approved Sustol (granisetron) extended-release injection for use in combination with other antiemetics in adults for the prevention of chemotherapy-induced nausea and vomiting.

Dronabinol Oral Solution Approved by FDA

By July 05, 2016

The FDA has approved Syndros (dronabinol oral solution) for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Emend for Oral Suspension Approved by the FDA

By December 21, 2015

The FDA has approved the New Drug Application (NDA) for Emend (aprepitant; Merck) for oral suspension for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients aged ≥6 months old.

Study: Sniffing Alcohol May Provide Nausea Relief

By December 08, 2015

Patients with nausea in the emergency department who sniffed pads saturated with isopropyl alcohol were twice as likely to find relief compared to nauseated patients that sniffed pads saturated with saline, a study published in Annals of Emergency Medicine has shown.

New Antiemetic for CINV Launched

By November 16, 2015

Tesaro announced the launch of Varubi (rolapitant) for use in adults for the prevention of delayed nausea and vomiting.

ASCO: Guideline Update for Antiemetics During Chemo

November 03, 2015

Oral combination of netupitant and palonosetron beneficial for prevention of nausea and vomiting

Cannabis Not Recommended to Prevent Post-op Nausea

October 14, 2015

Cannabis should not be used to prevent postoperative nausea and vomiting (PONV) because of unacceptable side effects and low effectiveness.

Electrocortical Therapy May Prevent Motion Sickness Without Drowsiness

September 09, 2015

A mild electrical current applied to the scalp - transcranial direct current stimulation (tDCS) - can prevent motion sickness, according to a study published in Neurology.

New Oral Antiemetic Agent Gains FDA Approval

By September 02, 2015

Tesaro announced that the Food and Drug Administration (FDA) has approved Varubi (rolapitant) tablets in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.